Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Novacyt ( (FR:ALNOV) ) has shared an update.
Novacyt has reported its latest monthly activity under a French-law liquidity agreement with Invest Securities, disclosing that during December 2025 the broker bought 20,020 ordinary shares and sold 15,467, leaving 119,466 shares held in treasury. The company confirmed that its total issued share capital stands at 70,626,248 ordinary shares, a key reference point for investors calculating disclosure thresholds under French securities rules, while reiterating that the liquidity agreement allows Invest Securities to operate independently to support trading in Novacyt’s stock within shareholder-approved buyback limits.
More about Novacyt
Novacyt S.A. is an international molecular diagnostics company focused on delivering genomic medicine through a broad portfolio of integrated technologies and services. It develops, manufactures and commercialises molecular assays and instrumentation that provide end-to-end workflows from sample to result across human health, animal health and environmental sectors, operating through clinical, instrumentation and research-use-only segments. Headquartered in Le Vésinet, France, with additional offices in the UK, Singapore, the US and Canada and commercial presence in more than 65 countries, Novacyt’s shares are traded on Euronext Growth in Paris and AIM in London.
Learn more about ALNOV stock on TipRanks’ Stock Analysis page.